CAR T Initiative

About CAR T

Cancer therapies have improved dramatically over the last several years, due to the development and discovery of novel therapies resulting from the science and research conducted at AACI cancer centers. Among these are chimeric antigen receptor T-cell (CAR T) therapies. CAR T therapies represent a critical advancement in treating malignancies, and evidence shows these therapies provide important clinical benefits to patients.

The AACI CAR T Initiative facilitates collaboration between subject matter experts at AACI’s member centers through webinars, listserv discussions, calls, meetings, and other activities. The steering committee has also submitted comments to the Centers for Medicare & Medicaid Services (CMS) on their proposed national coverage analysis.

Steering Committee

The CAR T Initiative Steering Committee helps guide the implementation of CAR T-cell therapy programs at AACI member centers across North America.


Peter Riedell, MD
The University of Chicago Medicine Comprehensive Cancer Center

View All Steering Committee Members

RECUR Initiative

RECUR Initiative

The RECUR initiative is a collaboration among the American Society for Transplantation and Cellular Therapy (ASTCT), AACI, and the Association of Community Cancer Centers (ACCC), aimed at revolutionizing the evaluation process for CAR T therapy to ensure timely and personalized care.

Through the RECUR initiative, ASTCT, AACI, and ACCC aim to empower oncologists, health care professionals, and patients alike with an understanding of the factors necessary for successful CAR T therapy, and the importance of early and timely referral for consultation with a center with expertise. By streamlining the efficiency of the referral process and fostering collaboration among medical experts, this initiative seeks to enhance patient outcomes and expand access to life-saving treatments.

Press release: ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T Therapy